Advanced Medical Isotope Corp. (OTCMKTS:ADMD) has seen a spectacular rise in sub peny lan d in recent weeks transformed into one of the top most traded stocks on the entire exchange on continued heavy accumulation and very positive investors sentiment.
ADMD move up has been helped along by the Wealthy Biotech Trader of PPCH fame who was compensated $50,000 a month by Advanced Medical Isotope Corporation. the Wealthy Biotech Trader’s controlling parent company has also been compensated 100,000 restricted preferred shares by ADMD.
Advanced Medical Isotope Corp. (OTCMKTS:ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.
The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans.
Last year ADMD announced its collaboration with IsoTherapeutics Group, LLC of Angleton, TX on the preclinical development of Y-90 based brachytherapy products including AMICs Y-90 RadioGel(TM) device.
AMIC selected IsoTherapeutics Group as its lead collaboration partner after a long search. IsoTherapeutics Group provides research and development services, including animal studies and early stage manufacturing, for the purpose of aiding customers and collaborators in the development of radionuclide-based drug and device products.
One of several Y-90 brachytherapy products in development by AMIC is the The Y-90 RadioGel™ device that may provide a safer, quicker and less expensive treatment to certain cancers, including tumors deemed inoperable. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
To Find out the inside Scoop on ADMD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
According to AMIC It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers with its Y-90 product suite. A new study published in the British Journal of Cancer claims 1 in 2 men and women will be diagnosed with a cancer at some point in their lives. AMIC’s mission employs in vivo delivery systems to aid medical practitioners and medical researchers in the treatment of diseases such as cancer, and the Y-90 brachytherapy products show excellent promise for this purpose.
According to the Wealthy Biotech Trader ”The Y-90 RadioGelä device, which OTC: ADMD holds 8 patents on and trademarks in about 40 different countries, is a biodegradable radioactive gel designed to be injected into any solid tumor as a liquid and then solidifies to hold the radiation in place, effectively taking over the cancerous tumor and destroying it from within. There is nothing on the market like ADMD Y-90 RadioGelä device. The devices design features make it suitable for use in a broad range of solid tumors and the company has highlighted potential opportunities in pancreatic and brain tumors. Once the product receives marketing clearance, the Company’s solid patent portfolio should secure the cash generation from this idea for many years.
Not only is the delivery system of the Y-90 RadioGel™ device completely novel in a way which multiplies its potential effectiveness, but the radioactive isotope (the cancer killing agent) contained in the gel, yttrium 90, is considered to be the new standard as it has one of the highest theoretical “therapeutic doses” of cancer killing power compared to the many other products on the market.”
On March 28 ADMD said Dr. Albert S. DeNittis MD, MS, FCPP has been appointed to the Company’s Medical Advisory Board. Dr. Albert S. DeNittis is currently is the Chief of Radiation Oncology at Lankenau Medical Center and Clinical Professor at Lankenau Insitute for Medical Research in Wynnewood, Pennsylvania and the Director of Radiation Oncology at Brodesseur Cancer Center in New Jersey. He is also the Principal Investigator and in charge of a grant awarded by the NIH for its National Cancer Oncology Research Program (NCORP) at Main Line Health.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $17 million market valuation ADMD has minimal assets, rising short term debt and no revenues to date. But this is an exciting story developing in small caps; The Company is focused on obtaining regulatory clearance by the FDA of the Y-90 RadioGel(TM) device which many say is superior to Selective Internal Radiation Therapy (SIRT) marketed by Sirtex Medical Limited which trades on the Amex at a $2 billion valuation. They are also commercializing into vet with many saying this initiative is going to be much bigger than anyone first thought, of course the the big catalyst will be FDA approval for human treatment. ADMD has been working hard to restructure their debt and they are proven masters at getting their story out there and attracting a loyal shareholder base that believes this one goes much higher. We will be updating on ADMD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ADMD.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ADMD either long or short and we have not been compensated for this article